State Street’s Tyra Biosciences TYRA Stock Holding History

State Street’s Portfolio TYRA Stock Details TYRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$68.4M	Buy	2,140,368 +924,290	+76%	+$30.6M	﹤0.01%	1680
2026 Q1	$46.6M	Buy	1,216,078 +466,615	+62%	+$15.1M	﹤0.01%	1780
2025 Q4	$19.7M	Buy	749,463 +320,991	+75%	+$5.9M	﹤0.01%	2285
2025 Q3	$5.99M	Buy	428,472 +9,488	+2%	+$108K	﹤0.01%	2926
2025 Q2	$4.01M	Buy	418,984 +4,996	+1%	+$47.5K	﹤0.01%	3037
2025 Q1	$3.85M	Buy	413,988 +6,415	+2%	+$83K	﹤0.01%	2983
2024 Q4	$5.67M	Buy	407,573 +22,841	+6%	+$415K	﹤0.01%	2913
2024 Q3	$9.05M	Buy	384,732 +16,248	+4%	+$341K	﹤0.01%	2667
2024 Q2	$5.89M	Buy	368,484 +76,250	+26%	+$1.31M	﹤0.01%	2846
2024 Q1	$4.79M	Buy	292,234 +26,880	+10%	+$441K	﹤0.01%	2940
2023 Q4	$3.68M	Buy	265,354 +5,896	+2%	+$76.3K	﹤0.01%	3091
2023 Q3	$3.57M	Buy	259,458 +3,081	+1%	+$45.7K	﹤0.01%	3084
2023 Q2	$4.37M	Buy	256,377 +24,288	+10%	+$352K	﹤0.01%	3059
2023 Q1	$3.73M	Buy	232,089 +15,463	+7%	+$184K	﹤0.01%	3102
2022 Q4	$1.65M	Sell	216,626 -1,362	-0.6%	-$9.63K	﹤0.01%	3435
2022 Q3	$1.92M	Buy	217,988 +3,963	+2%	+$36.2K	﹤0.01%	3426
2022 Q2	$1.53M	Buy	214,025 +10,345	+5%	+$82.4K	﹤0.01%	3539
2022 Q1	$2.18M	Buy	203,680 +72,670	+55%	+$863K	﹤0.01%	3533
2021 Q4	$1.84M	Buy	+131,010	New	+$2.6M	﹤0.01%	3662

Other funds holding TYRA

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

APMC

Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

State Street's TYRA Position: Q2 2026 in Review

State Street increased its Tyra Biosciences (TYRA) stake by 76% in Q2 2026, buying an estimated $30.6M and bringing the position to 2,140,368 shares worth $68.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1680.

State Street first reported a position in TYRA in Q4 2021 and has held it in 19 quarters since. 169 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

State Street held 2,140,368 shares of Tyra Biosciences worth $68.4M as of Q2 2026.
State Street bought 924,290 Tyra Biosciences shares in Q2 2026, an estimated $30.6M.
Tyra Biosciences made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1680 holding.
State Street first reported a position in Tyra Biosciences in Q4 2021 and has held it in 19 quarters since.
169 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.